ライフサイエンスコーパス: mg

1 n the expansion cohort were treated with 1.0 mg/kg luspatercept; dose titration up to 1.75 mg/kg was

2 mine (0.5 mg/kg), or high dose ketamine (1.0 mg/kg) after induction of anaesthesia, before surgical i

3 ible patients (serum phosphate =6.0 to <10.0 mg/dl and a 1.5-mg/dl increase from before washout) to o

4 of bevacizumab, 1.25 mg, or aflibercept, 2.0 mg, at baseline and every 4 weeks, with the primary outc

5 s elevated beyond the clinical cutoff of 3.0 mg/dL in 360 (51%) Tsimane participants.

6 Expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and renal cell

7 ther an initial oral dose of 200 000 IU (5.0 mg) colecalciferol (vitamin D3) followed by monthly 100

8 TBI values and the prevalence of low TBI (<0 mg/kg) in preschool children (PSC) (age range: 6-59 mo)

9 ansient asymptomatic hyponatremia at the 1.0-mg/kg dose level.

10 DNA films with surface densities up to 0.031 mg/mm(2) can reduce the transmittance of incident UVC an

11 The 0.05-mg/m3 and 0.35-mg/m3 exposure levels yielded similar ass

12 face, we found that low concentrations (0.09 mg/mL of the R5 bacteriophage, below the concentration r

13 icity analysis set: three at dose level 1 (1 mg/kg), three at dose level 2 (3 mg/kg), six at dose lev

14 emolysis in the concentrations studied (0-10 mg/ml) and improved colloidal stability of MSNR.

15 e level 2 (3 mg/kg), six at dose level 3 (10 mg/kg), and six at dose level 4 (20 mg/kg).

16 itabine 200 mg, and tenofovir alafenamide 10 mg, which was taken once per day for 48 weeks.

17 cannabinoid receptor 2 antagonist AM630 (10 mg/kg) or inverse agonist JTE907 (3 mg/kg) during immuni

18 abetuzumab govitecan once weekly at 8 and 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1

19 Durvalumab was administered at 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks with eithe

20 ts demonstrated that a low concentration (10 mg/L) Na humate solution in synthetic water significantl

21 f 40% or less to treatment with enalapril 10 mg twice daily or sacubitril/valsartan 97/103 mg twice d

22 Single oral dose of 10 mg of dexamethasone (n = 293) or identical placebo (n =

23 Escitalopram was given at a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter.

24 Lenalidomide dose escalation (to 5 mg or 10 mg per day) was permitted if the drug was well tolerated

25 e-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin.

26 Patients were treated with pembrolizumab 10 mg/kg every 2 weeks for up to 24 months.

27 defined as a total TXA dose greater than 10 mg/kg for 50% of the operative duration.

28 1 (DN-DISC1) mice were injected with THC (10 mg/kg) or vehicle for 10 days during mid-adolescence-equ

29 s 56% (29/52) and was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts.

30 ngle (n = 48; 7 consecutive cohorts, 0.3-100 mg/kg) or 4 weekly infusions (n = 16; 2 consecutive coho

31 either oseltamivir (75 mg), amantadine (100 mg), and ribavirin (600 mg) combination therapy or oselt

32 assigned to daily subcutaneous anakinra, 100 mg (n = 25), or placebo (n = 25) for 4 weeks and were fo

33 xaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspir

34 to receive second-line oral buparlisib (100 mg once daily) or placebo, plus intravenous paclitaxel (

35 o once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day).

36 ) followed by three cycles of docetaxel (100 mg/m(2); EC-D).

37 patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matchi

38 ) was demonstrated with BGJ398 doses >/= 100 mg in patients with FGFR1-amplified sqNSCLC and FGFR3-mu

39 pressure <120/80 mm Hg, fasting glucose <100 mg/dl, glycosylated hemoglobin <5.7%, and total choleste

40 sed 274 patients assigned to mepolizumab 100 mg and 277 assigned to placebo.

41 aroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin.

42 A, especially following doses lower than 100 mg, should directly undergo desensitization.

43 Vorinostat (100 mg twice daily) was started on day -10 and continued thr

44 o patients enrolled at a higher dose of 1000 mg/m(2), and both had a dose-limiting toxicity.

45 2 h intravenous infusion every 8 h) or 1000 mg meropenem (by 30-min intravenous infusion every 8 h)

46 After multivariable adjustment, each 1000-mg difference in usual 24-hour sodium excretion was dire

47 g twice daily or sacubitril/valsartan 97/103 mg twice daily (previously known as LCZ696 [200 mg twice

48 C) and high chlorophyll-a ( approximately 11 mg m(-3)).

49 mation operator26PFASs per tree was up to 11 mg for birch and 1.8 mg for spruce.

50 1), HL (12.69+/-0.16), and WS (12.80+/-0.11) mg GAEg(-1) respectively, and exhibited potent antioxida

51 nes in HIV-1 RNA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag pol

52 nce in combination with 2 daily doses of 120 mg/m2 of O6-benzylguanine.

53 size of four), to receive atezolizumab 1200 mg or chemotherapy (physician's choice: vinflunine 320 m

54 results support the use of raltegravir 1200 mg once daily for first-line therapy.

55 oclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile and evidence of sing

56 receive a daily capsule of resveratrol, 125 mg or 500 mg, or placebo for 6 months.

57 cessfully consumed doses were 0, 43, and 130 mg of protein in the placebo, VP100, and VP250 groups, r

58 leucovorin at 400 mg/m(2), irinotecan at 140 mg/m(2), and fluorouracil 400 mg/m(2) bolus followed by

59 d by 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 2.4 p

60 d by 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared with 3.3 p

61 -dependent once injection doses are above 15 mg kg(-1) : high dose expedited the renal excretion and

62 mg every 21 days with either bevacizumab 15 mg/kg every 21 days or 5 million units of IFN-alpha-2b t

63 mly assigned (1:1) to treatment group A (150 mg oral vismodegib per day for 12 weeks, then three roun

64 hibitor); and uptitration to alirocumab, 150 mg.

65 vismodegib daily) or treatment group B (150 mg oral vismodegib per day for 24 weeks, then three roun

66 containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 m

67 rugs (rivaroxaban: 20 mg QD, dabigatran: 150 mg BID, or warfarin) using 3-way propensity-matched samp

68 ne of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months.

69 of placebo daily followed by 12 weeks of 150 mg vismodegib daily) or treatment group B (150 mg oral v

70 of placebo daily followed by 8 weeks of 150 mg vismodegib daily).

71 ups (43 [88%] of 49 in the TRF-budesonide 16 mg/day group, 48 [94%] of 51 in the TRF-budesonide 8 mg/

72 e subcutaneous tocilizumab (at a dose of 162 mg) weekly or every other week, combined with a 26-week

73 oice: vinflunine 320 mg/m(2), paclitaxel 175 mg/m(2), or 75 mg/m(2) docetaxel) intravenously every 3

74 id (NA) concentrations ranging from 12 to 18 mg/L, significantly inhibited cell proliferation, reduce

75 Among individuals with LDL-C >/=190 mg/dL, pravastatin reduced the risk of coronary heart di

76 uced sulfide at similar levels to around 0.2 mg S/L at a ratio of 0.28 g S/g Fe3O4-Fe.

77 active doses of rovalpituzumab tesirine (0.2 mg/kg or 0.4 mg/kg every 3 weeks or 0.3 mg/kg or 0.4 mg/

78 l of a single ketamine infusion (saline, 0.2 mg/kg, 0.5 mg/kg).

79 its for aromatic amines in textiles (0.007-2 mg kg(-1)) were well below the limits legislated by the

80 emic clamp (arterial blood glucose 146 +/- 2 mg/dL) with portal GLC infusion.

81 te uptake from the CVVH circuit was 60 +/- 2 mg/min and provided 218 +/- 8 kcal/d.During CVVH there w

82 with background low-dose nitroglycerin (7.2 mg over 2 days) on early cardiac magnetic resonance imag

83 e subcutaneous administration of RG-101 at 2 mg/kg (n = 14) or 4 mg/kg (n = 14) or received a placebo

84 ilia were randomized to receive either BOS 2 mg or placebo twice daily for 12 weeks.

85 perties and a predicted low clinical dose (2 mg twice daily).

86 ection (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or macular

87 e intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 m

88 8 weeks later, they were subjected to LPS (2 mg/kg) or sepsis by cecal ligation and puncture (CLP).

89 tion (MIC) was 4 mg/L in 78 (69.6%) and </=2 mg/L in 34 (30.4%) isolates.

90 with on-treatment hsCRP concentrations of 2 mg/L or above (HR(adj)=0.90, 0.79-1.02, p=0.11).

91 ho achieved hsCRP concentrations less than 2 mg/L had a 25% reduction in major adverse cardiovascular

92 weeks of treatment with escitalopram (10-20 mg/day), duloxetine (30-60 mg/day), or CBT (16 50-minute

93 el 3 (10 mg/kg), and six at dose level 4 (20 mg/kg).

94 t a dose of 10 mg per day for 3 weeks and 20 mg per day thereafter.

95 milar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts.

96 ceiving a statin were given atorvastatin, 20 mg, and the following LLT intensification steps were app

97 assigned to treatment with octreotide LAR 20 mg every 21 days with either bevacizumab 15 mg/kg every

98 ither once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 100 mg of aspirin.

99 o receive either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) or placebo, admin

100 compared across the 3 drugs (rivaroxaban: 20 mg QD, dabigatran: 150 mg BID, or warfarin) using 3-way

101 r ruxolitinib dose reduction to less than 20 mg twice a day with at least one of grade 3 thrombocytop

102 has an acceptable toxicity profile up to 20 mg/kg and the maximum tolerated dose was not reached.

103 The MTD was 20 mg of carmustine applied once in combination with 2 dail

104 We determined 1,200 mg to be the recommended single-agent dose for future st

105 One dose-limiting toxicity occurred at 200 mg (the patient did not take at least 16 of 21 prescribe

106 In the dose-expansion phase, AZD3759 at 200 mg or 300 mg twice a day was administered to patients wi

107 ism and nutrition disorders (one [4%] at 200 mg twice a day and one [7%] at 300 mg twice a day).

108 iary and renal disorders (three [13%] at 200 mg twice a day), asthenia (one [7%] at 300 mg twice a da

109 ion, compared with placebo, bosutinib at 200 mg/d reduced kidney growth in patients with ADPKD.

110 trial and instead received melphalan at 200 mg/m(2) intravenously over 30 min on 1 day, followed by

111 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg, which was taken onc

112 sion, diabetes, and total cholesterol >/=200 mg/dL) were evaluated in multivariable models including

113 d half their standard TKI dose (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twi

114 twice daily (previously known as LCZ696 [200 mg twice daily]) in addition to guideline-directed medic

115 hemoglobin <5.7%, and total cholesterol <200 mg/dl.

116 ily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months.

117 emetrexed and cisplatin plus nintedanib (200 mg twice daily) or placebo followed by nintedanib plus p

118 zed PD-1-blocking antibody, at a dose of 200 mg every 3 weeks in relapsed and transformed CLL.

119 received 28-day cycles of pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days

120 ntries, were randomly assigned (1:1) to 2000 mg ceftazidime and 500 mg avibactam (by 2 h intravenous

121 Female smokers randomized to 21 mg nicotine (TNP; n=37) or placebo (PBO; n=43) transderm

122 dose of 800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid), the multidomain intervention

123 n of adults aged >/=19 y who consume >/=2300 mg/d would decline from 88% (95% CI: 86%, 91%) to 71% (9

124 hromycin MIC was 0.28 mg/L (range, <0.016-24 mg/L).

125 tem, to receive 1 year of oral neratinib 240 mg/day or matching placebo.

126 orouracil 400 mg/m(2) bolus followed by 2400 mg/m(2) over 46 h).

127 intravitreal injection of bevacizumab, 1.25 mg, or aflibercept, 2.0 mg, at baseline and every 4 week

128 ignificantly attenuated by carbenoxolone (25 mg/kg).

129 Mean azithromycin MIC was 0.28 mg/L (range, <0.016-24 mg/L).

130 ients with IMT (treated at 100, 165, and 280 mg/m(2)/dose) was 86%.

131 red to Controls (2.1 +/- 0.4 vs. 1.0 +/- 0.3 mg L(-1) , P = 0.047).

132 t treat and extend dosing of ranibizumab 0.3 mg with and without angiography-guided macular laser pho

133 scular safety of ranibizumab, 0.5 mg and 0.3 mg, compared with sham with and without laser in DME.

134 (0.2 mg/kg or 0.4 mg/kg every 3 weeks or 0.3 mg/kg or 0.4 mg/kg every 6 weeks), 11 (18%) of 60 assess

135 level 1 (1 mg/kg), three at dose level 2 (3 mg/kg), six at dose level 3 (10 mg/kg), and six at dose

136 containing 300 g raw carrot (providing 27.3 mg beta-carotene and 18.7 mg alpha-carotene).

137 .65-1.93) for participants with serum CRP >3 mg/L.

138 M630 (10 mg/kg) or inverse agonist JTE907 (3 mg/kg) during immunization heightens the intensity and b

139 In wild-type (WT) mice, LY2828360 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-in

140 Low-dose naltrexone, 3 mg nightly, titrated to 4.5 mg nightly in 2 patients.

141 participants with serum CRP levels of 1 to 3 mg/L and 1.12 (95% CI, 0.65-1.93) for participants with

142 Participants received oral cabotegravir 30 mg tablets or matching placebo once daily during a 4 wee

143 ts legislated by the European Union (EU) (30 mg kg(-1)) and those in urine and wastewater (0.004-1.5

144 t) to one of six tenapanor regimens (3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily) or plac

145 ns (3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily) or placebo for 4 weeks.

146 MAT1A-KO mice were also given SAMe (30 mg/kg/day for 8 weeks); liver samples were collected and

147 al, patients were randomized to tolvaptan 30 mg/day or placebo.

148 infections and infestations (one [7%] at 300 mg twice a day), and metabolism and nutrition disorders

149 0 mg twice a day), asthenia (one [7%] at 300 mg twice a day), infections and infestations (one [7%] a

150 %] at 200 mg twice a day and one [7%] at 300 mg twice a day).

151 food challenges to an eliciting dose of 300 mg or less of peanut protein.

152 se-expansion phase, AZD3759 at 200 mg or 300 mg twice a day was administered to patients with either

153 doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3 months.

154 tients were randomly assigned to receive 300 mg intravenous zanamivir (n=201), 600 mg intravenous zan

155 onset </=4 days or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care

156 otherapy (physician's choice: vinflunine 320 mg/m(2), paclitaxel 175 mg/m(2), or 75 mg/m(2) docetaxel

157 Steady-state concentrations (34 mg/kg) and BAF values (0.05) obtained for the snail dire

158 The 0.05-mg/m3 and 0.35-mg/m3 exposure levels yielded similar associations.

159 0 days followed by clemastine fumarate (5.36 mg orally twice daily) for 60 days (group 2).

160 to receive either clemastine fumarate (5.36 mg orally twice daily) for 90 days followed by placebo f

161 ensitivity of lactate levels greater than 36 mg/dL for 30-day mortality was 20.0% (95% CI, 8.9%-39.1%

162 log10 RT-qPCR reduction between 300 and 360 mg-min/L.

163 iotics (amoxicillin and clavulanic acid, 375 mg, to be taken 3 times a day for 1 week).

164 ssigned to 6-month therapy with NIAT and 375 mg/m(2) intravenous rituximab on days 1 and 8 (n=37) or

165 tuximab maintenance therapy at a dose of 375 mg per square meter of body-surface area administered ev

166 of rovalpituzumab tesirine (0.2 mg/kg or 0.4 mg/kg every 3 weeks or 0.3 mg/kg or 0.4 mg/kg every 6 we

167 0.4 mg/kg every 3 weeks or 0.3 mg/kg or 0.4 mg/kg every 6 weeks), 11 (18%) of 60 assessable patients

168 1400 nM) adhered to a fibrin matrix (0.1-0.4 mg/mL fibrinogen, 10 nM thrombin) under a variety of ven

169 (five [2%]) in the trastuzumab emtansine 2.4 mg/kg weekly group compared with pneumonia (four [4%]),

170 istration of RG-101 at 2 mg/kg (n = 14) or 4 mg/kg (n = 14) or received a placebo (n = 2/dosing group

171 mab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, and dexamethasone 40 mg weekly.

172 infected adults were randomized to receive 4 mg of PENNVAX-G DNA delivered intramuscularly by Bioject

173 to vascular-targeted photodynamic therapy (4 mg/kg padeliporfin intravenously over 10 min and optical

174 minimum inhibitory concentration (MIC) was 4 mg/L in 78 (69.6%) and </=2 mg/L in 34 (30.4%) isolates.

175 lacebo-controlled trial with atorvastatin 40 mg/day for 9 weeks in 14 SPG5 patients with 27-hydroxych

176 4 mg daily for 21 days, and dexamethasone 40 mg weekly.

177 or standard-dose subcutaneous enoxaparin (40 mg once daily for 10+/-4 days) for venous thromboprophyl

178 as fecal fat >7 g/day and urine oxalate >40 mg/day.

179 iduals with T2DM and without diabetes to <40 mg/dL, which is well below the normal fasting plasma glu

180 either adalimumab (at a dose of 20 mg or 40 mg, according to body weight) or placebo, administered s

181 All subjects received 40 mg of rosuvastatin daily for 8 to 12 weeks, when the non

182 dyskinesia score was also reduced in the 40 mg/day group (-1.9 compared with -0.1).

183 oxaliplatin at 65 mg/m(2), leucovorin at 400 mg/m(2), irinotecan at 140 mg/m(2), and fluorouracil 400

184 notecan at 140 mg/m(2), and fluorouracil 400 mg/m(2) bolus followed by 2400 mg/m(2) over 46 h).

185 lts with HCC who tolerated sorafenib (>/=400 mg/day for >/=20 of last 28 days of treatment), progress

186 INTERPRETATION: A single dose of 400 mg DSM265 was well tolerated and had causal prophylactic

187 toclax in combination with rituximab was 400 mg.

188 6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and tra

189 ne kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occupancy in patients with c

190 les sulfur loading and content as high as 46 mg cm(-2) and 70 wt% with an electrolyte/sulfur ratio of

191 d cerebrovascular safety of ranibizumab, 0.5 mg and 0.3 mg, compared with sham with and without laser

192 e the efficacy and safety of ranibizumab 0.5 mg treat-and-extend (T&E) versus monthly regimens in pat

193 kg twice per day for 7 days, followed by 0.5 mg/kg per day for 3 days).

194 ed to receive placebo or hydrocortisone (0.5 mg/kg twice per day for 7 days, followed by 0.5 mg/kg pe

195 cebo (normal saline), low-dose ketamine (0.5 mg/kg), or high dose ketamine (1.0 mg/kg) after inductio

196 le ketamine infusion (saline, 0.2 mg/kg, 0.5 mg/kg).

197 lowing intravenous infusion of ketamine (0.5 mg/kg).

198 mg/m(2) per cycle [0.8 mg/m(2) on day 1; 0.5 mg/m(2) on days 8 and 15 of a 21-28 day cycle for </=6 c

199 ned (1:1:1) to receive oral rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaro

200 Apixaban 2.5 mg twice daily in patients on hemodialysis resulted in d

201 amin D3) followed by monthly 100 000 IU (2.5 mg) colecalciferol or equivalent placebo dosing.

202 treatment groups: Group A received IVB (2.5 mg/0.1 mL) 1-3 days before PPV, while Group B received I

203 before PPV, while Group B received IVB (2.5 mg/0.1 mL) 5-10 days before PPV.

204 /day) or matching oral placebo capsules (2.5 mg/day) for 28-day cycles, until disease progression or

205 tem to receive either oral lenalidomide (2.5 mg/day) or matching oral placebo capsules (2.5 mg/day) f

206 mparing hydroxyurea to placebo at 20 +/- 2.5 mg/kg per day for 12 months.

207 se naltrexone, 3 mg nightly, titrated to 4.5 mg nightly in 2 patients.

208 Apixaban 5 mg twice daily led to supratherapeutic levels in patient

209 0 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once

210 comparable with that of the standard dose (5 mg twice daily) in patients with preserved renal functio

211 l risk was similar between women taking </=5 mg warfarin daily and women treated with LMWH.

212 Patients received 5 mg/kg belatacept every 2 weeks, and the dosing interval

213 Lenalidomide dose escalation (to 5 mg or 10 mg per day) was permitted if the drug was well

214 Over 2 years, compared with PRP, 0.5-mg ranibizumab as given in this trial is within the $500

215 erum phosphate =6.0 to <10.0 mg/dl and a 1.5-mg/dl increase from before washout) to one of six tenapa

216 oses equivalent to five tablets per day of 5-mg hydrocodone.

217 P=0.03), above the 90th percentile for the 5-mg dose in patients with preserved renal function.

218 ely, when compound 23 was administered at 50 mg/kg via single dose ip.

219 ebo or one of three doses of canakinumab (50 mg, 150 mg, or 300 mg) given subcutaneously once every 3

220 KI dose (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months

221 reviously reported for the OSPW-OF (i.e., 50 mg/L) due to unknown additive and/or synergistic interac

222 use only a small amount of ovary sample (<50 mg) is needed for the approach established in the curren

223 tween involved and uninvolved FLC (dFLC) <50 mg/L cannot be assessed for response and are excluded fr

224 inistered at 10 mg/kg every 2 weeks or 1,500 mg every 4 weeks with either olaparib tablets twice dail

225 ssigned (1:1) to 2000 mg ceftazidime and 500 mg avibactam (by 2 h intravenous infusion every 8 h) or

226 different NP concentrations (20, 50 and 500 mg/Kg) in sediments amended with different percentage of

227 rated dose of CPI-613 was established at 500 mg/m(2) when used in combination with modified FOLFIRINO

228 daily capsule of resveratrol, 125 mg or 500 mg, or placebo for 6 months.

229 ypoglycemia with a blood glucose level of 55 mg per deciliter (3.1 mmol per liter) or below was signi

230 with cirrhosis and ascites to rifaximin 550 mg twice a day (n = 36) or placebo twice a day (n = 18).

231 ody-containing regimen were treated with 560 mg ibrutinib orally once daily until progression or unac

232 e plus pertuzumab (trastuzumab emtansine 3.6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenanc

233 d 10 mg/kg, or two times per week at 4 and 6 mg/km on weeks 1 and 2 of 3-week repeated cycles.

234 in area under the concentration-time curve 6 mg/mL x min; trastuzumab 8 mg/kg loading dose, 6 mg/kg m

235 L x min; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as

236 Systemic treatment of rats with 6 mg/kg 6c either simultaneously or 18 h prior to systemic

237 citalopram (10-20 mg/day), duloxetine (30-60 mg/day), or CBT (16 50-minute sessions).

238 ns (n = 16; 2 consecutive cohorts, 30 and 60 mg/kg per infusion) of TNT009 or placebo.

239 A phase 1 study established 60 mg/m(2) guadecitabine for 5 days as an effective treatme

240 One group was given 60 mg iron at 0800 h (+/-1 h) on consecutive days for 14 da

241 mice received vehicle or BACE inhibitor (60 mg/kg) starting at 7 wk of age.

242 ndomly assigned to receive 12 wk of iron (60 mg; Fe group), MMNs (14 other micronutrients; MMN group)

243 iduals on antiretroviral therapy received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks.

244 ays (n = 115) after iron supplementation (60 mg iron as ferrous fumarate daily).

245 21,162 patients to ASA alone, ticagrelor 60 mg twice daily + low-dose ASA, or ticagrelor 90 mg twice

246 The benefit of ticagrelor 60 mg was consistent at each subsequent landmark (year 1 ha

247 ve 300 mg intravenous zanamivir (n=201), 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltami

248 (L803-mts), starting from 4 hours after 600 mg/kg dose of APAP, resulted in early initiation of live

249 taxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 3 weeks (DC) or three cycles of epirubici

250 bicin (90 mg/m(2)) and cyclophosphamide (600 mg/m(2)) followed by three cycles of docetaxel (100 mg/m

251 ive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at

252 4 days or 5-6 days) to receive 300 mg or 600 mg intravenous zanamivir, or standard-of-care (75 mg ora

253 mg), amantadine (100 mg), and ribavirin (600 mg) combination therapy or oseltamivir monotherapy twice

254 eceive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intrav

255 Average urine oxalate excretion was 61 mg/day; there was no correlation between fecal fat and u

256 irsen received weekly doses of custirsen 640 mg intravenously after three loading doses of 640 mg.

257 travenously after three loading doses of 640 mg.

258 with modified FOLFIRINOX (oxaliplatin at 65 mg/m(2), leucovorin at 400 mg/m(2), irinotecan at 140 mg

259 ot (providing 27.3 mg beta-carotene and 18.7 mg alpha-carotene).

260 res improved by 4.2 and 4.8 points in the 70-mg and 140-mg erenumab groups, respectively, as compared

261 res improved by 5.5 and 5.9 points in the 70-mg and 140-mg erenumab groups, respectively, as compared

262 g/kg luspatercept; dose titration up to 1.75 mg/kg was allowed, and patients could be treated with lu

263 travenous zanamivir, or standard-of-care (75 mg oral oseltamivir) twice a day for 5-10 days; patients

264 igned to receive six cycles of docetaxel (75 mg/m(2)) and cyclophosphamide (600 mg/m(2)) every 3 week

265 nd trastuzumab plus pertuzumab (docetaxel 75 mg/m(2); carboplatin area under the concentration-time c

266 600 mg intravenous zanamivir (n=209), or 75 mg oral oseltamivir (n=205) twice a day; 11 patients dis

267 e 320 mg/m(2), paclitaxel 175 mg/m(2), or 75 mg/m(2) docetaxel) intravenously every 3 weeks.

268 ion system to receive either oseltamivir (75 mg), amantadine (100 mg), and ribavirin (600 mg) combina

269 imibe therapy; add-on alirocumab therapy, 75 mg (a PCSK9 inhibitor); and uptitration to alirocumab, 1

270 male mice were fed a Western diet (WD) +/-75 mg PDX twice daily by oral gavage for 14 days.

271 in (starting dose 1.8 mg/m(2) per cycle [0.8 mg/m(2) on day 1; 0.5 mg/m(2) on days 8 and 15 of a 21-2

272 s per tree was up to 11 mg for birch and 1.8 mg for spruce.

273 ive inotuzumab ozogamicin (starting dose 1.8 mg/m(2) per cycle [0.8 mg/m(2) on day 1; 0.5 mg/m(2) on

274 ty (0.02 +/- 2.0 compared with -0.03 +/- 2.8 mg . min(-1), respectively; P = 0.9) or first-phase insu

275 roup, 48 [94%] of 51 in the TRF-budesonide 8 mg/day, and 42 [84%] of 50 controls).

276 radermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4

277 tion-time curve 6 mg/mL x min; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pert

278 ere applied: uptitration to atorvastatin, 80 mg; add-on ezetimibe therapy; add-on alirocumab therapy,

279 either extended-duration oral betrixaban (80 mg once daily for 35-42 days) or standard-dose subcutane

280 or placebo, plus intravenous paclitaxel (80 mg/m(2) on days 1, 8, 15, and 22) in 28 day treatment cy

281 was change from baseline to week 6 in the 80 mg/day group compared with the placebo group on the Abno

282 in AIMS dyskinesia score was -3.2 for the 80 mg/day group, compared with -0.1 for the placebo group,

283 r injections of long-acting cabotegravir 800 mg or saline placebo at 12 week intervals.

284 a fixed-dose tablet containing darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofov

285 ribed reduced starting dose sorafenib (< 800 mg/d per os).

286 es a day providing a total daily dose of 800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid

287 ibed standard starting dosage sorafenib (800 mg/d per os) versus that of patients who were prescribed

288 for future studies in FL and DLBCL, with 800 mg being sufficient to consistently achieve durable resp

289 ates were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated 10-year overall

290 stuzumab emtansine 3.6 mg/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel,

291 aminated cabbage (tissue concentration of 86 mg/kg; BAF of 0.36).

292 tment electrochemical system, with up to 880 mg of Nd L(-1) achieved within 4 days (at 40 A m(-2)).

293 ggregate group were 152 +/- 10 and 178 +/- 9 mg/dL, respectively.

294 weeks (DC) or three cycles of epirubicin (90 mg/m(2)) and cyclophosphamide (600 mg/m(2)) followed by

295 twice daily + low-dose ASA, or ticagrelor 90 mg twice daily + low-dose ASA.

296 given placebo or 100, 300, 450, 600, or 900 mg latiglutenase daily for 12 or 24 weeks.

297 eeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) ver

298 h binding (mean density, 4,447 +/- 1,128 dpm/mg of tissue) with the antagonist.

299 a low binding (mean density, 844 +/- 168 dpm/mg of tissue) with the agonist whereas 12 had a high bin

300 omen with high urinary FSH values (>11.5 mIU/mg creatinine [n = 69]) did not have a significantly dif